238 related articles for article (PubMed ID: 28250345)
1. Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity.
Elmeligie S; Ahmed EM; Abuel-Maaty SM; Zaitone SA; Mikhail DS
Chem Pharm Bull (Tokyo); 2017; 65(3):236-247. PubMed ID: 28250345
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
6. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
7. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
[TBL] [Abstract][Full Text] [Related]
8. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities.
Jaballah MY; Serya RAT; Saad N; Khojah SM; Ahmed M; Barakat K; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1573-1589. PubMed ID: 31852269
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
[TBL] [Abstract][Full Text] [Related]
10. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
13. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
17. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in-vitro cytotoxic evaluation of novel pyridazin-4-one derivatives.
Mojahidi S; Rakib el M; Sekkak H; Abouricha S; Benchat N; Mousse HA; Zyad A
Arch Pharm (Weinheim); 2010 May; 343(5):310-3. PubMed ID: 20222064
[TBL] [Abstract][Full Text] [Related]
19. Discovery and synthesis of novel allylthioaralkylthiopyridazines: their antiproliferative activity against MCF-7 and Hep3B cells.
Park HS; Kim C; Park MS
Arch Pharm Res; 2015; 38(5):791-800. PubMed ID: 24925344
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
